MarketVue®: Diabetic Retinopathy
The MarketVue®: Diabetic Retinopathy market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing
Methodology:
Research for the MarketVue®: Diabetic Retinopathy report is supported by 3 qualitative interviews with key opinion leaders, a quantitative survey with 19 U.S. physicians and secondary research.
Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)
Key companies mentioned:
• Regeneron Pharmaceuticals
• Novartis
• Hoffmann-La Roche
• Adverum Biotechnologies
• Regenexbio
• Oxurion
• Graybug Vision
• Kubota Vision
• Opthea
Key drugs mentioned:
• Aflibercept (Eylea)
• Ranibizumab (Lucentis)
• Bevacizumab (Avastin)
• Faricimab (Vabysmo)
• Ranibizumab port delivery system (Susvimo)
• Brolucizumab (Beovu)
• RGX-314
• ADVM-022
• THR-149
• GB-102
• Emixustat
• OPT-302
• THR-687
Please note: the online download version of this report is for a global site license.
- 1. DISEASE OVERVIEW
- Blood vessel impairment underlies vision impairment in diabetic retinopathy
- Hallmarks of diabetic retinopathy
- Figure 1.1. Stages of diabetic retinopathy
- 2. EPIDEMIOLOGY & PATIENT POPULATIONS
- Disease definition
- Figure 2.1. Diagnosed prevalent cases of diabetic retinopathy by region
- Table 2.1. Diagnosed prevalent and drug-treated diabetic retinopathy patients in the US and EU5
- Figure 2.2. Segmentation of total prevalent cases of diabetic retinopathy by severity
- 3. CURRENT TREATMENT
- Treatment goals
- Figure 3.1. Treatment goals for diabetic retinopathy
- Standard of care
- Figure 3.2. Patient share of anti-VEGF treatment
- Table 3.1. Current anti-VEGF usage by retinal specialists
- Treating physicians
- Referring physicians
- Figure 3.3. Diagnosis and treatment flow for diabetic retinopathy
- Must-know treatment dynamics for diabetic retinopathy
- Barriers to patient care
- Figure 3.4. Percent of retina specialists rating factor as impactful
- Figure 3.5. Potential timeline of diabetic retinopathy market evolution
- Is earlier treatment with current therapies on the horizon? Not so fast.
- Figure 3.6. Retina specialist experimentation with anti-VEGF for NPDR
- 4. UNMET NEED
- Treatment-related unmet needs
- Figure 4.1. Top unmet needs in diabetic retinopathy
- Figure 4.2. Percentage of retina specialists ranking unmet need in their top two
- Unmet need by type of diabetic retinopathy
- Figure 4.3. Percentage of retina specialists citing extremely high unmet need by disease type
- Early prevention and reversal of disease progression
- 5. PIPELINE ANALYSIS
- Overview
- Figure 5.1. Number of emerging therapies addressing unmet needs in diabetic retinopathy
- Gene therapy has caught the eye of retinal specialists
- Figure 5.2. Percent of retina specialists rating target/approach as promising
- Table 5.1. Emerging therapies in clinical development for diabetic retinopathy
- Retina specialists’ pipeline knowledge
- Figure 5.3. Percent of retina specialists familiar with emerging therapy
- 6. VALUE & ACCESS
- Overview
- Table 6.1. Annual cost and sales of anti-VEGF therapies
- CMS is the predominant payer for diabetic retinopathy patients
- Figure 6.1. Payer mix for diabetic retinopathy
- Figure 6.2. Phase III biosimilars on the horizon for Eylea and Lucentis
- 7. METHODOLOGY
- Primary market research methodology
- Epidemiology methodology
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook